EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bristol-Myers Squibb Co's Enterprise Value is $188,062 Mil.
Bristol-Myers Squibb Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was $14,281 Mil. Therefore, Bristol-Myers Squibb Co's EV-to-FCF for today is 13.17.
The historical rank and industry rank for Bristol-Myers Squibb Co's EV-to-FCF or its related term are showing as below:
BMY'
s EV-to-FCF Range Over the Past 10 Years
Min: 7.93 Med: 18.53 Max: 380.98
Current: 13.17
During the past 13 years, the highest EV-to-FCF of Bristol-Myers Squibb Co was 380.98. The lowest was 7.93. And the median was 18.53.
BMY's EV-to-FCF is ranked better than 69.42% of 484
companies
in the Drug Manufacturers industry
Industry Median: 22.62
vs BMY: 13.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-17), Bristol-Myers Squibb Co's stock price is $74.56.
Bristol-Myers Squibb Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $3.010. Therefore, Bristol-Myers Squibb Co's PE Ratio for today is 24.77.
Competitive Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co EV-to-FCF Distribution
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's EV-to-FCF falls into.
Bristol-Myers Squibb Co EV-to-FCF Calculation
Bristol-Myers Squibb Co's EV-to-FCF for today is calculated as:
Bristol-Myers Squibb Co's current Enterprise Value is $188,062 Mil.
Bristol-Myers Squibb Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $14,281 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (NYSE:BMY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Bristol-Myers Squibb Co's PE Ratio for today is calculated as:
Bristol-Myers Squibb Co's share price for today is $74.56.
Bristol-Myers Squibb Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bristol-Myers Squibb Co EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.43(0.58%) Volume: 5,346,282 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:BMY has been successfully added to your 
